NPJ Vaccines最新文献_第3页

Influenza mRNA vaccine with engineered panhandle-forming UTRs provides potent, dose-sparing protection against seasonal influenza viruses. 具有工程化的长柄状utr的流感mRNA疫苗提供了有效的、剂量节约的季节性流感病毒保护。

IF 6.5 1区医学

NPJ Vaccines Pub Date : 2026-04-27 DOI: 10.1038/s41541-026-01463-3

Yifan Xu, Xuehua Wan, Mingzhuo Chen, Benchi Li, Qian Weng, Qin Wang, Zhiliang Hu, Yongxiang Yi, Junwei Li

{"title":"Influenza mRNA vaccine with engineered panhandle-forming UTRs provides potent, dose-sparing protection against seasonal influenza viruses.","authors":"Yifan Xu, Xuehua Wan, Mingzhuo Chen, Benchi Li, Qian Weng, Qin Wang, Zhiliang Hu, Yongxiang Yi, Junwei Li","doi":"10.1038/s41541-026-01463-3","DOIUrl":"https://doi.org/10.1038/s41541-026-01463-3","url":null,"abstract":"Influenza viruses pose a persistent threat to global public health, causing widespread respiratory illness and significant morbidity. Vaccination remains the most effective strategy to reduce the burden of both seasonal and pandemic influenza. mRNA vaccines represent a promising alternative to conventional vaccine platforms due to their rapid development, flexibility, and high efficacy. Nonetheless, optimizing non-coding regulatory elements such as untranslated regions (UTRs) remains crucial for enhancing mRNA vaccine performance. In this study, we designed a novel UTR derived from the influenza A virus M segment, engineered to form optimal panhandle structures through selective base-pair enhancing mutations (M1 + 2), aiming to improve mRNA translation efficiency and immunogenicity. Using both reporter and HA antigen-encoding mRNAs, we demonstrated that the M1 + 2 UTR significantly enhanced protein expression in vitro and in vivo compared to unmodified UTRs and the canonical α-globin UTR control. In a murine model, low-dose (0.1 μg) vaccination with HA mRNA-lipid nanoparticles (LNPs) incorporating the M1 + 2 UTR elicited robust innate, humoral, and T cell-mediated immune responses, and conferred complete protection against lethal challenge with seasonal influenza strains, including H1N1, H3N2, and IBV. Our findings underscore the potential of rational UTR design in developing more efficacious and dose-sparing mRNA vaccines.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":6.5,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An open repository of COVID-19 vaccine mandate studies with a worked scoping review of quasi-experimental evidence. 开放的COVID-19疫苗授权研究库，并对准实验证据进行工作范围审查。

IF 6.5 1区医学

NPJ Vaccines Pub Date : 2026-04-25 DOI: 10.1038/s41541-026-01454-4

Fabio I Martinenghi, Tanka Prashad Ojha, Amy Thomasson, Bianca Devsam, Shevaun Drislane, Sophie Vasiliadis, Chiara Berardi, Aregawi Gebremariam, Alessia Dipalma, Teresa Gavaruzzi, Jeremy K Ward, Francesco Paolucci, Margie Danchin, Mesfin Genie, Katie Attwell, Christopher C Blyth

{"title":"An open repository of COVID-19 vaccine mandate studies with a worked scoping review of quasi-experimental evidence.","authors":"Fabio I Martinenghi, Tanka Prashad Ojha, Amy Thomasson, Bianca Devsam, Shevaun Drislane, Sophie Vasiliadis, Chiara Berardi, Aregawi Gebremariam, Alessia Dipalma, Teresa Gavaruzzi, Jeremy K Ward, Francesco Paolucci, Margie Danchin, Mesfin Genie, Katie Attwell, Christopher C Blyth","doi":"10.1038/s41541-026-01454-4","DOIUrl":"https://doi.org/10.1038/s41541-026-01454-4","url":null,"abstract":"Vaccine mandates were widely implemented against COVID-19, and a large and multidisciplinary literature has emerged as a result, covering fields such as epidemiology, economics, ethics, and law. We compiled an openly available repository of this literature, including 503 studies on COVID-19 vaccine mandates. We identified them through a manual multi-database search and performed the data extraction using a large language model. The dataset stores information, for each study, on the scope and sanctions of the relevant mandate(s), the study design, target population, outcomes, and themes, allowing users to quickly navigate this complex literature. We use the dataset to present key statistical facts and insights about this literature, and we leave to other scholars the opportunity of interrogating it further. As a worked example, we conduct a narrative review of quasi-experimental studies on COVID-19 vaccine mandates. These consistently show short-run increases in first-dose uptake following mandate announcements, with limited evidence on long-run uptake and downstream social, health, and economic outcomes. We provide all data and code to support secondary analyses and future evidence syntheses.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":6.5,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prefusion-stabilized SARS-CoV-2 spike reshapes antigenic hierarchy and antibody targeting against conserved and occluded epitopes. 预灌注稳定的SARS-CoV-2刺突重塑抗原等级和针对保守和封闭表位的抗体靶向。

IF 6.5 1区医学

NPJ Vaccines Pub Date : 2026-04-25 DOI: 10.1038/s41541-026-01464-2

Shintaro Oishi, Ryutaro Kotaki, Hisham M Dokainish, Saya Moriyama, Shinichiro Ota, Takayuki Matsumura, Tomohiro Takano, Taishi Onodera, Yu Adachi, Kazutaka Terahara, Masanori Isogawa, Kazuhiko Katayama, Takashi Sato, Masaharu Shinkai, Yoshimasa Takahashi

{"title":"Prefusion-stabilized SARS-CoV-2 spike reshapes antigenic hierarchy and antibody targeting against conserved and occluded epitopes.","authors":"Shintaro Oishi, Ryutaro Kotaki, Hisham M Dokainish, Saya Moriyama, Shinichiro Ota, Takayuki Matsumura, Tomohiro Takano, Taishi Onodera, Yu Adachi, Kazutaka Terahara, Masanori Isogawa, Kazuhiko Katayama, Takashi Sato, Masaharu Shinkai, Yoshimasa Takahashi","doi":"10.1038/s41541-026-01464-2","DOIUrl":"https://doi.org/10.1038/s41541-026-01464-2","url":null,"abstract":"Receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike contains multiple classes of antibody epitopes that are associated with diverse neutralizing activities. Although both natural infection and vaccination robustly elicit RBD-reactive and neutralizing antibodies, the spike antigenic structures presented to the immune system may differ, leading to qualitative differences in the antibody responses. Using large and well-controlled cohorts, we show that the neutralizing potency index (NPI), calculated as the ratio of neutralizing titer to RBD IgG titer, is approximately fivefold lower in vaccine recipients than in convalescent individuals, independent of disease severity, comorbidities, or demographic factors. This reduction in NPI is associated with enhanced antibody targeting to non-neutralizing, yet conserved and structurally occluded RBD epitope. Molecular dynamics (MD) simulations together with the binding assay demonstrate that the occluded epitope is allosterically exposed by stabilizing mutations introduced into the vaccine spike antigen, a process mediated by a highly extended RBD-up conformation. Collectively, our findings demonstrate that RBD conformational modulation by stabilizing mutations shapes vaccine antigenicity and likely alters the epitope landscape of antibody responses.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":6.5,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adjuvant-induced macrophage activation compromises BA71ΔCD2-mediated protection against African swine fever virus. 佐剂诱导的巨噬细胞激活损害BA71ΔCD2-mediated对非洲猪瘟病毒的保护。

IF 6.5 1区医学

NPJ Vaccines Pub Date : 2026-04-24 DOI: 10.1038/s41541-026-01461-5

Aida Tort-Miró, Sergio Montaner-Tarbes, David Marín-Moraleda, Jordana Muñoz-Basagoiti, Yan Zeng, María Jesús Navas, Marta Muñoz, Paula Monleon, Judith González-Oliver, Beatriz Martín-Mur, Marc Caballé, Margarita Artigues, Anna Esteve-Codina, Virginia Aragon, Enric Vidal, Àlex Cobos, Francesc Accensi, Sonia Pina-Pedrero, Elena Garcia-Fruitós, Fernando Rodríguez, Jordi Argilaguet

{"title":"Adjuvant-induced macrophage activation compromises BA71ΔCD2-mediated protection against African swine fever virus.","authors":"Aida Tort-Miró, Sergio Montaner-Tarbes, David Marín-Moraleda, Jordana Muñoz-Basagoiti, Yan Zeng, María Jesús Navas, Marta Muñoz, Paula Monleon, Judith González-Oliver, Beatriz Martín-Mur, Marc Caballé, Margarita Artigues, Anna Esteve-Codina, Virginia Aragon, Enric Vidal, Àlex Cobos, Francesc Accensi, Sonia Pina-Pedrero, Elena Garcia-Fruitós, Fernando Rodríguez, Jordi Argilaguet","doi":"10.1038/s41541-026-01461-5","DOIUrl":"https://doi.org/10.1038/s41541-026-01461-5","url":null,"abstract":"While effective subunit vaccines against African swine fever (ASF) are still under development, live attenuated vaccines (LAVs) remain the only approach capable of inducing robust protective immunity, though biosafety concerns limit their field use. Thus, further research is required to improve LAV safety while maintaining its immunogenicity. Because both the ASF virus (ASFV) and derived LAVs suppress macrophage innate responses, we hypothesized that adjuvants could restore functionality of LAV-infected cells, allowing dose reduction and consequently minimizing the risk of adverse events. To test this, we intranasally vaccinated pigs with a suboptimal dose of the LAV BA71ΔCD2, either alone or combined with two immunostimulatory adjuvants derived from Rothia nasimurium. Both immunostimulants enhanced the in vitro responsiveness of BA71ΔCD2-infected macrophages, which acquired antigen-presenting features. However, in vivo, both adjuvants lowered humoral and cellular responses induced by BA71ΔCD2, consequently decreasing protection against lethal challenge. Further in vitro analyses demonstrated that adjuvant-activated macrophages acquired an antiviral state, limiting LAV replication. These results suggest the hypothesis that reduced vaccine efficacy might result from insufficient antigen production. Overall, the study indicates that combining adjuvants with ASFV-based LAVs would require a fine-tune macrophage activation to enhance functionality without excessively inhibiting viral replication.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":6.5,"publicationDate":"2026-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Author Correction: Immunisation of koalas against Chlamydia pecorum results in significant protection against chlamydial disease and mortality. 作者更正：对考拉进行pecorum衣原体免疫接种可显著预防衣原体疾病和死亡率。

IF 6.5 1区医学

NPJ Vaccines Pub Date : 2026-04-22 DOI: 10.1038/s41541-026-01419-7

Samuel Phillips, Jon Hanger, Julien Grosmaire, Ahmed Mehdi, Martina Jelocnik, Jessie Wong, Peter Timms

引用次数: 0

Efficacy of the meningococcal vaccine against Neisseria gonorrhoeae: a randomised clinical trial (MenGO). 淋病奈瑟菌脑膜炎球菌疫苗的疗效：一项随机临床试验（MenGO）。

IF 6.5 1区医学

NPJ Vaccines Pub Date : 2026-04-22 DOI: 10.1038/s41541-026-01422-y

Caroline Thng, Sharareh Eskandari, Fengyi Jin, Ian Hughes, Andrew E Grulich, Maree O'Sullivan, Evgeny A Semchenko, Kate L Seib

{"title":"Efficacy of the meningococcal vaccine against Neisseria gonorrhoeae: a randomised clinical trial (MenGO).","authors":"Caroline Thng, Sharareh Eskandari, Fengyi Jin, Ian Hughes, Andrew E Grulich, Maree O'Sullivan, Evgeny A Semchenko, Kate L Seib","doi":"10.1038/s41541-026-01422-y","DOIUrl":"https://doi.org/10.1038/s41541-026-01422-y","url":null,"abstract":"Neisseria gonorrhoeae (NG) causes significant morbidity globally, and no licensed vaccine currently exists. Observational studies suggest the four-component meningococcal B (4CMenB) vaccine may provide cross-protection against NG. We conducted MenGO, an open-label, randomized controlled trial to evaluate the efficacy, safety, and immunogenicity of 4CMenB against NG in gay and bisexual men (GBM). Participants were randomized 1:1 to receive two doses of 4CMenB, or no vaccine, and were followed for 2 years with 3-monthly visits. 4CMenB vaccination did not significantly reduce gonorrhoea incidence (incidence rate ratio 0.78 (95% confidence interval (CI) 0.40-1.51;p = 0.457), and no study-related serious adverse events occurred. The vaccine was immunogenic against NG, with higher serum bactericidal activity (hSBA) median titres at 6 months in vaccinated compared to unvaccinated participants (4 [interquartile range (IQR) 2-8] vs 2 [IQR 2-2];p = 0.0021). However, hSBA titres did not increase in participants with an NG infection at the time of vaccination (2 [IQR 2-2] to 2 [IQR 2-4];p = 0·999), whereas those without NG infection showed an increase from baseline to 6 months (2 [IQR 2-4] to 6 [IQR 2-16];p = 0.0089). This study is limited by its small sample size based on an assumed vaccine efficacy of >67% and was impacted by the COVID-19 pandemic. These findings provide important information for current 4CMenB vaccines programmes and gonorrhoea vaccine development and implementation.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":6.5,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of in vitro airway epithelial model to assess immune response and safety of mucosal adjuvants. 体外气道上皮模型的建立以评估黏膜佐剂的免疫反应和安全性。

IF 6.5 1区医学

NPJ Vaccines Pub Date : 2026-04-22 DOI: 10.1038/s41541-026-01459-z

David Acosta, Mohammad Rubel Hoq, Kazuyo Takeda, Chad D Costley, Hana Golding, Marina Zaitseva

{"title":"Development of in vitro airway epithelial model to assess immune response and safety of mucosal adjuvants.","authors":"David Acosta, Mohammad Rubel Hoq, Kazuyo Takeda, Chad D Costley, Hana Golding, Marina Zaitseva","doi":"10.1038/s41541-026-01459-z","DOIUrl":"https://doi.org/10.1038/s41541-026-01459-z","url":null,"abstract":"Mucosal vaccines delivered intranasally or by inhalation, can elicit localized immunity that protects mucosal tissues at the site of infection and may reduce transmission of respiratory viruses, including respiratory syncytial virus (RSV), influenza virus, and SARS-CoV-2. Many mucosal vaccine candidates incorporate adjuvants to enhance and broaden immune response, underscoring the need for safe and effective formulations targeting the respiratory mucosa. Here, we employed differentiated human nasal and bronchial epithelial cells (hNEC and hBEC) cultured at air-liquid interface (ALI) to evaluate the soybean oil-in-water intranasal NE01 adjuvant, recently assessed clinically. Kinetic and dose-response studies showed that hBECs were more sensitive than hNEC to the cytopathic effect of NE01 as evidenced by loss of barrier integrity, reduced viability, and Interleukin-8 production. Spiking Cetylpyridinium chloride (CPC), a component of NE01, into a squalene oil-in-water adjuvant identified CPC as a potential contributor to the observed cytotoxicity in hBEC. Lower NE01 concentrations did not compromise hBEC viability or barrier function, indicating concentration-dependent effects and establishing thresholds for epithelial perturbation. The data provide proof-of-concept supporting the ALI system for assessing the effects of mucosal adjuvants on Upper and Lower respiratory tract epithelia during the early stages of development. This approach may help prioritize candidates while reducing reliance on animal use in preclinical evaluation.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":6.5,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Structural and genetic signatures of two classes of HCV E2 neutralizing face antibodies from non-human primates immunized with a recombinant E1E2. 重组E1E2免疫非人灵长类动物两类HCV E2中和面部抗体的结构和遗传特征

IF 6.5 1区医学

NPJ Vaccines Pub Date : 2026-04-21 DOI: 10.1038/s41541-026-01449-1

Yen T K Nguyen, Fang Chen, Erick Giang, Swati Saha, Lynn A Ueno, Christopher Chen, Corey T Watson, Netanel Tzarum, Ian A Wilson, Mansun Law, Robyn L Stanfield

{"title":"Structural and genetic signatures of two classes of HCV E2 neutralizing face antibodies from non-human primates immunized with a recombinant E1E2.","authors":"Yen T K Nguyen, Fang Chen, Erick Giang, Swati Saha, Lynn A Ueno, Christopher Chen, Corey T Watson, Netanel Tzarum, Ian A Wilson, Mansun Law, Robyn L Stanfield","doi":"10.1038/s41541-026-01449-1","DOIUrl":"10.1038/s41541-026-01449-1","url":null,"abstract":"Hepatitis C continues to be a significant public health problem despite advancements in antiviral therapeutics. To eliminate this disease, an effective vaccine against new infections and re-infections is needed. However, to date only one Hepatitis C virus (HCV) envelope protein (E1E2) immunogen, developed by Chiron Inc., has been tested in a Phase I clinical trial (ClinicalTrials.gov identifier NCT00500747). To establish a benchmark for elicitation of broadly neutralizing antibodies (bnAbs) by E1E2, we previously immunized non-human primates (NHPs) with this immunogen and isolated monoclonal nAbs that exhibit neutralization potency comparable to human nAbs. Here we show that NHP nAbs, encoded by germline genes IGHV1-138*01 and IGHV4-NL_5*01 (homologs of human IGHV1-69*10 and IGHV4-59*12, respectively), recognize a relatively conserved E2 region (neutralizing face) proximal to antigenic region 3 (AR3). These NHP AR3-targeting nAbs share highly similar binding modes to human AR3-targeting nAbs, suggesting a similarity in human and NHP immune responses to the same HCV immunogen.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":6.5,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147729594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dual-route H5N1 vaccination induces systemic and mucosal immunity in murine and bovine models. 在小鼠和牛模型中，双路H5N1疫苗接种可诱导全身和粘膜免疫。

IF 6.5 1区医学

NPJ Vaccines Pub Date : 2026-04-21 DOI: 10.1038/s41541-026-01460-6

Joshua Wiggins, Adthakorn Madapong, Eric A Weaver

{"title":"Dual-route H5N1 vaccination induces systemic and mucosal immunity in murine and bovine models.","authors":"Joshua Wiggins, Adthakorn Madapong, Eric A Weaver","doi":"10.1038/s41541-026-01460-6","DOIUrl":"https://doi.org/10.1038/s41541-026-01460-6","url":null,"abstract":"Highly pathogenic H5N1 avian influenza (clade 2.3.4.4b) has spread widely among dairy cattle herds since early 2024, causing major economic losses. This zoonotic event emphasizes the urgent need for H5 vaccines eliciting strong, durable, cross-reactive immune responses in cows. To address this, we immunized mice and cattle with a centralized consensus H5 vaccine, localizing near the central node of the human H5 phylogenetic tree. The vaccine was delivered using serotype-switched adenoviral vectors in a prime-boost regimen, combined with intramuscular and intranasal coadministration to target systemic and mucosal immunity and elicit strong humoral and cellular immune responses. This approach strategically integrates multiple innovative features: centralized consensus immunogens, mucosal targeting, and vector serotype switching aimed at maximizing immune protection against H5N1 viruses. Our results show that vaccination elicits strong humoral and cellular immunity in both mice and calves. In challenge experiments, vaccinated mice were fully protected against lethal infection with divergent H5N1 strains, including A/bovine/Ohio/B24OSU-439/2024. Vaccine-induced immunity was consistent across species, supporting the translatability of the mouse model findings to cattle. Overall, our findings represent a promising approach for immunizing key livestock, including cattle, against highly pathogenic avian influenza H5N1, mitigating agricultural losses, and reducing the risk of zoonotic transmission.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":6.5,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

BPZE1 vaccination induces IL-17⁺ and IL-22⁺ CD4⁺ T cells associated with nasal mucosal secretory IgA responses in humans: effects on virulent Bordetella pertussis colonisation. BPZE1疫苗接种诱导与人鼻黏膜分泌IgA反应相关的IL-17+和IL-22+ CD4+ T细胞：对百日咳强毒杆菌定植的影响

IF 6.5 1区医学

NPJ Vaccines Pub Date : 2026-04-18 DOI: 10.1038/s41541-026-01443-7

Alison R Hill, Diane F Gbesemete, Tyween Coutinho, Muktar Ibrahim, Jay R Laver, Peter Goldstein, Stephanie Noviello, Keith Rubin, Saul N Faust, Camille Locht, Robert C Read, Adam P Dale

{"title":"BPZE1 vaccination induces IL-17+ and IL-22+ CD4+ T cells associated with nasal mucosal secretory IgA responses in humans: effects on virulent Bordetella pertussis colonisation.","authors":"Alison R Hill, Diane F Gbesemete, Tyween Coutinho, Muktar Ibrahim, Jay R Laver, Peter Goldstein, Stephanie Noviello, Keith Rubin, Saul N Faust, Camille Locht, Robert C Read, Adam P Dale","doi":"10.1038/s41541-026-01443-7","DOIUrl":"https://doi.org/10.1038/s41541-026-01443-7","url":null,"abstract":"Pertussis remains a major public health challenge due to the inability of current acellular vaccines to prevent Bordetella pertussis colonisation and transmission. The live-attenuated intranasal vaccine, BPZE1, has shown efficacy in protecting against infection following challenge with virulent B. pertussis, but the immune mechanisms underpinning this protective effect are poorly defined. In this study, we demonstrate that intranasal vaccination with BPZE1 induced circulating CD4+ T cells of Th17 and Th22 effector phenotype. These responses correlated positively with BPZE1-induced secretory IgA (SIgA) responses, suggesting coordinated induction of mucosal immunity. Among BPZE1 recipients who developed breakthrough infection following virulent B. pertussis challenge, higher vaccine-induced SIgA titres were significantly associated with reduced colonisation density. By contrast, BPZE1-induced serum IgA and IgG titres were not associated with reduced colonisation density. These findings identify a Th17/Th22-SIgA immune axis as a feature of BPZE1 vaccination and support the hypothesis that BPZE1-induced SIgA may contribute to reduced B. pertussis colonisation density in participants with virulent B. pertussis breakthrough infection despite BPZE1 vaccination.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":6.5,"publicationDate":"2026-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147717586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0